Quince TherapeuticsQNCX.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 9, 2026, Quince Therapeutics (QNCX.O) trades at a P/E of N/A, P/B of N/A, P/S of N/A, and a dividend yield of N/A.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/S historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data).
Cross-sectional valuation: P/B percentile data for Quince Therapeutics is still accumulating, both within its industry and across the broader market.
Shareholder return highlight: Dividend Yield (Total Shareholder Yield unavailable, using Dividend Yield instead) is N/A; its historical percentile over the trailing long-term window is still accumulating data.
Quince Therapeutics operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: QNCX · QNCX
Want the full picture on whether Quince Therapeutics (QNCX.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | N/A | — | — | — | — | — | — |
| P/B (MRQ) | N/A | — | — | — | — | — | — |
| P/S (TTM) | N/A | — | — | — | — | — | — |
| Dividend Yield | N/A | — | — | — | — | — | — |
| Buyback + Div Yield | N/A | — | — | — | — | — | — |